Super exciting news for the HD community: Novartis´s announcement of the new the global Phase 3 trial for Votoplam will be called INVEST-HD. The trial will test how well Votoplam  works and the safety in a larger group of participants. This is the next step in the previously investigated Phase 2 PIVOT-HD trial.

Votoplam, previously called PTC-518, is an oral medicine being developed for Huntington’s Disease. It works by helping the body make more of the healthy huntingtin protein and less of the harmful form that leads to disease development. This could help slow or change the course of HD.